Share/Refer CSATC

Doctor Administers medical Marijuana

Keeping You Informed

CSATC - New Jersey Medical Marijuana Dispensary


Category: Dispensary News

CSATC’s Improvements, New Strains and More

Since CSATC entered the cannabis industry in New Jersey, our goal has always been to continue to improve the Medical Marijuana Program. We recognize the realities of being a patient in New Jersey; a program structure that is expensive and one that limits patients’ access to high grade medical cannabis. Considering that there are only five alternative treatment centers in New Jersey, from the onset, CSATC has made constant efforts to provide patients with greater accessibility to the most affordable and the highest quality medicine.

CSATC is involved in constant research and development. We recently purchased new extraction instrumentation to improve the quality of our extract products. The new upgrade enhances our extracting ability by eliminating the post decarboxylation process. Eliminating this process minimizes the degradation of concentrate, which results in an increased clarity in our oil. In addition, our extract process has recently been enhanced, and utilizes a two stage distillation process to fully remove waxes allowing for higher concentration recovery and less non-targeted compounds. These recent improvements in our extracting abilities are noticeable in the physical clarity of our topical oil as well as improved taste, smell and provide an increase in the clarity of effects among our extract products.

Largest and most consistent variety of medical cannabis strains. Our growers are constantly working to improve strains by methodically adjusting grow conditions to maximize the medicinal components for patients. We are currently growing six new strains that will be announced before the end of the year. CSATC’s patient base is constantly growing, and to match the demand, our facility has been approved to expand an additional 23,000 square feet giving room for an additional 500 lights. In the short term, this will allow CSATC to grow enough medicine to supply our growing patient base. Our long term plan is to turn our existing building into our cultivation and processing location, and open a larger, better suited CSATC dispensary across the street from our existing location.

These efforts will enhance CSATC’s ability to provide the highest quality medical cannabis strains and products at even more affordable prices. Our mission is to help relieve the pain and suffering of patients with serious diseases, and in order to accomplish this goal, CSATC has implemented different initiatives to make our medical cannabis more accessible and affordable for patients in the New Jersey Medical Marijuana Program.

When CSATC opened, our prices were set below market value, but we knew that this wouldn’t be the end of our effort to improve patients’ access to medicine. Since then, we have expanded our hours of operation instituting the largest range of hours in the state for patients to purchase medicinal cannabis.

CSATC is unique in that our prices can be taken at face value. The prices patients see already includes the 6.875 percent state sales tax. CSATC is currently lobbying for the removal of the medical cannabis state sales tax, which would further reduce prices for patients. Over the past three months CSATC has reduced flower prices by more than 20 percent on over 12 top strains, and has increased the variety of featured strains in hopes that more patients will find the right strains for their debilitating medical condition. We also offer additional discounts including the Veteran’s Discount of 20%, the Compassionate Discount of 20% for those on government assistance and a Minor’s Discount of 40%.

As part of our hands-on approach to improve the New Jersey cannabis industry for patients, Executive Director George Schidlovsky has positioned himself on the board of directors for the New Jersey CannaBusiness Association, a powerful and active association whose mission is to guide the decision makers and regulators in the budding cannabis industry to understand and respect the needs of the CannaBusiness community.


Posted on in category: Cannabis News, New Jersey News, Dispensary News | Comments Off on CSATC’s Improvements, New Strains and More

CSATC Educational Event Crohn’s and Colitis June 22

Beyond providing increasing accessibility to medicinal cannabis and being an active voice in the developing cannabis industry, CSATC will continue to provide education events for patients. We are finding that patients are enjoying our educational events, and that they provide an even greater sense of community surrounding our ATC. If you haven’t had the chance to attend our patient educational events, please stay tuned for upcoming events. We are hosting a Crohn’s and Colitis event on June 22. For more information or to RSVP, please call CSATC at (856) 933-8700.

Posted on in category: Dispensary News, Educational Events | Comments Off on CSATC Educational Event Crohn’s and Colitis June 22

Are you familiar with CSATC’s Topical, Lozenge and Lotion?

Producing relaxing and pain-relieving effects, patients find these products helpful with chronic pain, inflammation, arthritis, migraines and muscle spasms.

These products contain a total of 300 mg of THC and 30 mg of CBD, and are equal to the purchase of an 1/8 ounce out of a patient’s allotted recommendation. The Topical, Lozenge, and Lotion are designed to contain 30 separate controlled doses, each dose contains 10 mg of TProduct-LotionHC to 1 mg of CBD.

The Cannabis Infused Cocoa Butter Lotion, comprised of cannabis extract, coconut oil and cocoa butter, delivers active ingredients to the bloodstream through the skin offering localized relief.

Product-TopicalWith similar effects, the Topical consists of a supercritical CO2 cannabis extract and up to 5% Vegetable Glycerin, this product is sold as one syringe filled with .6 g of medicine.


The Lozenges are meant to dissolve slowly in a patient’s mouth being absorbed through the mucosal membrane. They come in flavors such as pineapple, raspberry, strawberry, peach and watermelon.


For more information about our strains click hereand for more information about our extracts click here.

Posted on in category: Dispensary News, Products | Tagged , , , , , | Comments Off on Are you familiar with CSATC’s Topical, Lozenge and Lotion?

CSTAC Enhances Patients’ Access to Affordable Medicine

In response to patient and physician suggestions, on April 1, 2017, Compassionate Sciences ATC implemented the new CSATC Affordable Medicine Act by increasing accessibility and improving affordability of medicine for all qualifying participants in the New Jersey Medicinal Marijuana Program (NJMMP). Since inception in 2015, CSATC has performed extensive research and development on implementing cost efficient, high quality production processes for the highest quality medicine. This research has improved CSATC’s efficiency by identifying cost reductions in supplies, energy, nutrients, overhead and running costs. Now we are passing along these savings to all patients in the state of New Jersey.

The CSATC Affordable Medicine Act Creates a Three-tiered Price Program for Qualified Patients. CSATC will also continue to provide an additional Compassionate Discount of 20% and the Veteran Discount of 10% on all flower purchases for those who qualify. CSATC will also continue to provide an additional Compassionate Discount of 20% and the Veteran Discount of 10% on all flower purchases for those who qualify.

Tier I – strains include:

• Agent Orange (AO), a hybrid (50×50) sativa x indica;
• Albert’s Super Silver Sour Diesel (ASD), a sativa-dominant hybrid;
• Blackberry Kush (BK), an indica-dominant hybrid;
• Blue Tahoe (BTH), an indica-dominant hybrid;
• Blue Dream (BD), a sativa-dominant hybrid;
• Girl Scout Cookies (GSC), a sativa-dominant hybrid that’s high in CBG;
• Ghost OG Moonshine (GOG), a sativa-dominant hybrid;
• Golden Goat (GG), a sativa-dominant hybrid;
• Lavender (LAV), an indica-dominant hybrid;
• Wappa (WAP), an indica-dominant hybrid; and
• Willy Jack (WJ), an indica-dominant hybrid.

Tier II – strains include: 

• AC/DC (ACDC), a sativa-dominant hybrid that’s high in CBD;
• Blueberry Silvertip (BST), an indica-dominant hybrid that’s high in CBG and CBN;
• Blue Widow 1 (BW1), an indica-dominant hybrid that’s high in CBG;
• Chem Dawg (CD), a hybrid (50 x 50) sativa x indica;
• Gorilla Glue #4 (GL#4), a hybrid (50 x 50) sativa x indica;
• Hash Plant (HP), a pure-indica strain;
• Hibiscus Sunrise (HS), a sativa-dominant hybrid;
• Hindu Kush (HK), a pure-indica strain;
• Silver Tip (ST), a sativa-dominant hybrid that’s high in CBG;
• Sunburn (SB), a sativa-dominant hybrid;
• Super Lemon Haze (SLH), a sativa-dominant hybrid that’s high in CBG; and
• Very Berry (VB), a sativa-dominant hybrid.

Tier III – strains include:

• Various strains will be available weekly as Small Bud and featured strains.
• High quality Vape Mix and Pre Rolls will be affordably priced while supplies last.

Posted on in category: Dispensary News, Products | Tagged , , , | Comments Off on CSTAC Enhances Patients’ Access to Affordable Medicine

Expanded Hours of Operation

On April 1, 2017, CSATC expanded its hours of operation by opening at 10:00 a.m., every day, seven days a week, excluding certain national holidays. New patient consultations and appointments will now begin at 11:00 a.m., and our closing time will remain 7:00 p.m. With this change, CSATC will provide patients with the widest range of operating hours of any ATC in the state of New Jersey.

Posted on in category: Dispensary News | Comments Off on Expanded Hours of Operation

Administration of Medicinal Cannabis

Medicinal Cannabis is delivered to the bloodstream using inhalation, oral and topical methods of administration. In New Jersey, forms of administration include vaporizers and smoking, edible products such as lozenges, sublingual formulations, creams and lotions.

Inhalation is the fastest-acting method of administration other than intravenous injection. When inhaled, the active ingredients of Cannabis pass directly into the bloodstream from the lungs. Peak blood levels are achieved within 5-20 minutes and the pharmacological activity is typically within 3 hours. Examples are smoking, vaporizers and nebulizers.

Oral administration is a slower-acting method because the active ingredients of Cannabis must pass through the gastrointestinal tract during digestion before entering the bloodstream. Pharmacological effects occur in 30-90 minutes. Oral administration also alters the chemistry of therapeutical ingredients by “first pass” metabolism in the digestive tract. Examples are edibles and sublingual forms.

Topical forms are typically used as creams or lotions to treat localized pain and discomfort, delivering active ingredients to the bloodstream through the skin Examples are topical lotions.



• Compassionate Sciences offers over 23 varieties and strains of flower “bud” containing a complete profile of cannabinoids included but not limited to THCA, CBDA, CBGA and other essential cannabinoids that provide patient experience.

Compassionate Sciences offers indica, sativa and hybrid strains that are recommended for the treatment of all qualifying medical conditions.

Patients find flower “bud” to be helpful with all conditions and side effects such as depression, stress, chronic pain, fatigue, anxiety and many more.

Lozenges-on-trayOral Administration
• Compassionate Sciences offers Lozenges containing Tetrahydrocannabinol and Cannabidiol, both of which have medicinal benefits.

These soft tablets are meant to dissolve slowly in the patient’s mouth and absorbed into the blood stream through the mucosal membrane.

Patients find lozenges to be helpful with pain relief, inflammation, muscles spasms, cramps, menstrual pain and migraines.



Product Description:
Cannabis infused Lozenges

1/8 oz container
Contains 30 individual Lozenge troches
Total: 300mg THC
30mg CBD
Each troche is a single dose containing 10mg THC : 1mg CBD
Effects: Relaxing, Pain Relief
Conditions: Chronic Pain, Inflammation, Arthritis, Migraines, Muscle Spasms


Oil-webTopical Administration
• Compassionate Sciences offers a topical in the form of a pure-clean cannabis extract derived through supercritical extraction with CO2 as the active solvent. Compassionate Sciences also provides a Cocoa Butter based lotion. Both contain Tetrahydrocannabinol and Cannabidiol.

When administered properly these topical formulas do not produce psychotropic effects, but instead offer fast acting, long lasting, localized relief.

Topical cannabis products are helpful in relieving localized pain, inflammation, burns, both bacterial and fungal skin infections, itching and psoriasis, muscle spasms and cramps and migraines or headaches.

Topical products are also commonly used to improve skin elasticity, reduce acne, shrink skin abnormalities such as warts or skin tags and used as personal lubricants.

Product Description:
Cannabis infused Cocoa Butter Lotion

1/8 oz container
Total: 300mg THC
30mg CBD
30 doses / container
Each (1mL or 1g ) dose = 10mg THC:1mg CBD
Ingredients: Extract, Coconut Oil, Cocoa Butter
Effects: Relaxing, Pain Relief
Conditions: Chronic Pain, Inflammation, Arthritis, Migraines, Muscle Spasms
Product Description:
Cannabis Topical Oil

1/8 oz container
Contains one syringe with 0.6g of medicine
Total: 300mg THC
30mg CBD
30 doses / syringe
Each dose = 2 marked graduated units on syringe (10mg THC:1mg CBD)
Ingredients: Extract and Up to 5% VG if applicable
Effects: Relaxing, Pain Relief
Conditions: Chronic Pain, Inflammation, Arthritis, Migraines, Muscle Spasms

Posted on in category: Dispensary News, Products | Comments Off on Administration of Medicinal Cannabis

New Jersey’s medical marijuana industry posted a banner year in 2016

pngNew Jersey’s medical marijuana industry posted a banner year in 2016, with patient counts ballooning 76% and sales volume doubling thanks to a series of small changes to the state’s MMJ program and the opening of two new dispensaries.

This is welcome news for a program that has struggled to enroll patients amid high MMJ prices, weak doctor participation and limited access to treatment centers.

Over the course of 2016, New Jersey added roughly 4,600 patients to the MMJ program, ending the year at nearly 11,000. Sales of MMJ jumped by an even greater degree, as the state’s five dispensaries sold a combined 2,694 pounds of cannabis in 2016, a 119% increase from the previous year.

Two of those five dispensaries – Breakwater Alternative Treatment Center in Cranbury and Compassionate Sciences Alternative Treatment Center in Bellmawr– came online in late 2015. The addition of these dispensaries is responsible for much of the growth in sales but is likely driving patient counts as well.

Compassionate Sciences, for example, opened in September 2015 in western New Jersey, just outside of Philadelphia. The dispensary is located in an area of the state not covered by the other four dispensaries, and it ended 2016 with significantly more MMJ sales than all its competitors.

Foundation Harmony, the sixth and final dispensary to be awarded a license, is still undergoing examination from the state before being allowed to open.

These two new dispensaries also added some much-needed competition to the market, lowering MMJ prices in the state to about $300 per ounce, down from highs of nearly $500 per ounce.

New Jersey prices were previously some of the highest of any MMJ market in the nation and likely prevented many would-be patients from seeking an MMJ recommendation. State data shows that 45% of registered patients qualified for and received a reduced application fee. The discount is given to patients who receive some form of government assistance, including – but not limited to – Medicaid and disability benefits.

Beyond the addition of new dispensaries, the state has also made changes to the MMJ program that should further boost patient counts.

Despite his misgivings, Republican Gov. Chris Christie signed legislation adding PTSD to the list of qualifying MMJ conditions last September. By the end of the year, nearly 500 patients with PTSD qualified for the program, accounting for approximately 4% of all MMJ patients in the state.

In July, New Jersey’s health department instituted a program that allows the public to petition to have ailments added to the list of qualifying MMJ conditions. According to the Department of Health, 45 conditions met the program’s guidelines and were passed on to the Medicinal Medical Review Panel. The panel will hold meetings throughout 2017 to consider those petitions.

The program still faces challenges, however, as industry observers believe it still needs more licensed physicians willing to recommend marijuana, while restrictions on the types of MMJ products allowed to be sold may lead potential patients to the black market.



New Jersey Department of Health
Posted on in category: New Jersey News, Dispensary News | Comments Off on New Jersey’s medical marijuana industry posted a banner year in 2016